Molecular targeted therapies: ready for 'prime time' in biliary tract cancer
Affiliation
Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK;Issue Date
2020
Metadata
Show full item recordCitation
Lamarca A, Barriuso J, McNamara MG, Valle JW. Molecular targeted therapies: ready for prime time in biliary tract cancer. J Hepatol. 2020.Journal
Journal of HepatologyDOI
10.1016/j.jhep.2020.03.007PubMed ID
32171892Additional Links
https://dx.doi.org/10.1016/j.jhep.2020.03.007Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.jhep.2020.03.007
Scopus Count
Collections
Related articles
- Current and emerging therapies for advanced biliary tract cancers.
- Authors: Kam AE, Masood A, Shroff RT
- Issue date: 2021 Nov
- Ivosidenib: an investigational drug for the treatment of biliary tract cancers.
- Authors: Angelakas A, Lamarca A, Hubner RA, McNamara MG, Valle JW
- Issue date: 2021 Apr
- Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?
- Authors: Aitcheson G, Mahipal A, John BV
- Issue date: 2021 Apr
- Molecular-driven treatment for biliary tract cancer: the promising turning point.
- Authors: Persano M, Puzzoni M, Ziranu P, Pusceddu V, Lai E, Pretta A, Donisi C, Pinna G, Spanu D, Cimbro E, Parrino A, Liscia N, Mariani S, Dubois M, Migliari M, Scartozzi M
- Issue date: 2021 Nov
- Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives.
- Authors: Rizzo A, Ricci AD, Brandi G
- Issue date: 2021 Apr